BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29

• Press Releases

  Neuropathic Pain Market worth $11.53 Billion by 2030, Coherent Market Insights

  November 25, 2024

   · 

  1 min read
• Press Releases

  Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

  November 25, 2024

   · 

  6 min read
• Press Releases

  Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics

  November 25, 2024

   · 

  5 min read
• Press Releases

  CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

  November 25, 2024

   · 

  7 min read
• Press Releases

  Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

  November 25, 2024

   · 

  1 min read
• 

  Neurodegenerative disease

  Biohaven Drug Misses in Phase III for SMA, Will Be Tested in Obesity

  While taldefgrobep alfa failed to show improved motor function in spinal muscular atrophy, treated patients saw a marked reduction in body fat. Biohaven plans to launch a Phase II trial in obesity by the end of the year.

  November 25, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Regulatory

  Days After BridgeBio Approval, FDA Agrees to Review Alnylam’s Amvuttra in ATTR-CM

  The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, potentially giving Pfizer’s tafamidis franchise another competitor.

  November 25, 2024

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Alzheimer’s disease

  Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III

  Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”

  November 25, 2024

   · 

  2 min read

   · 

  Annalee Armstrong
• Press Releases

  Foresight Diagnostics and Leading Global Cancer Center to Present New Data on Foresight CLARITY™ Ultra-Sensitive MRD Detection in Early-Stage Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

  November 25, 2024

   · 

  3 min read
• Press Releases

  Neural Therapeutics Undertakes Multiple Initiatives to Defer and Eliminate a Significant Portion of Financial Obligations

  November 25, 2024

   · 

  9 min read